

Brentuximab vedotin (Synonyms: BRENTUXIMAB [VANDF])



Catalog Number: 176856

Product name

Brentuximab vedotin (Synonyms: BRENTUXIMAB [VANDF])

Specificity

Human TNFRSF8 / CD30

Antibody description

Anti-TNFRSF8 / CD30 Antibody (Brentuximab vedotin)

Preparation

Recombinant expression and purified from CHO cells.

Formulation

0.1 M Pro-Ac, 20 mM Arg, pH 5.0

Storage

-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.

Clonality

Monoclonal


Ig Type

IgG1

Applications


ELISA

Validations




SDS-PAGE

Anti-TNFRSF8 / CD30 Antibody (brentuximab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



SEC-HPLC

The purity of Anti-TNFRSF8 / CD30 Antibody (brentuximab vedotin) is 98.99%, determined by SEC-HPLC.




HIC

MMAE is conjugated by sulfhydryl coupling, the DAR value of Anti-TNFRSF8 / CD30 Antibody (brentuximab vedotin) antibody is 4.0.

Brentuximab vedotin (Synonyms: BRENTUXIMAB [VANDF])



Catalog Number: 176856



Bioactivity: ELISA

Immobilized human CD30 His at 2 µg/mL can bind Anti-TNFRSF8 / CD30 Antibody (brentuximab vedotin), EC50 is 0.006007 µg/mL.